JPH09511519A - β−受容体ブロッカーおよび局所麻酔剤の新規な組合せ - Google Patents
β−受容体ブロッカーおよび局所麻酔剤の新規な組合せInfo
- Publication number
- JPH09511519A JPH09511519A JP7526272A JP52627295A JPH09511519A JP H09511519 A JPH09511519 A JP H09511519A JP 7526272 A JP7526272 A JP 7526272A JP 52627295 A JP52627295 A JP 52627295A JP H09511519 A JPH09511519 A JP H09511519A
- Authority
- JP
- Japan
- Prior art keywords
- combination
- local anesthetic
- receptor blocker
- pharmaceutically acceptable
- metoprolol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.治療に使用するための、同時にまたは連続的に投与されるβ−受容体ブロッ カー、そのエナンチオマーまたはその薬学的に許容しうる塩と局所麻酔剤または その薬学的に許容しうる塩の組み合せ(但し、リドカインを除く)。 2.β−受容体ブロッカーは非選択的β−受容体ブロッカーである請求項1記載 の組み合せ。 3.β−受容体ブロッカーは選択的β−受容体ブロッカーである請求項1記載の 組み合せ。 4.非選択的β−受容体ブロッカーはアルプレノロールである請求項2記載の組 み合せ。 5.選択的β−受容体ブロッカーはメトプロロールである請求項3記載の組み合 せ。 6.メトプロロールはその(R)−形態である請求項5記載の組み合せ。 7.メトプロロールはその(S)−形態である請求項5記載の組み合せ。 8.局所麻酔剤はロピバカインである請求項4記載の組み合せ。 9.局所麻酔剤はメピバカインである請求項4記載の組み合せ。 10.局所麻酔剤はブピバカインである請求項4記載の組み合せ。 11.局所麻酔剤はトカイニドである請求項4記載の組み合せ。 12.(R)−メトプロロールはその塩酸塩形態であり、そして局所麻酔剤はロピバ カインである請求項6記載の組み合せ。 13.(S)−メトプロロールはその塩酸塩形態であり、そして局所麻酔剤はロピバ カインである請求項7記載の組み合せ。 14.メトプロロールはメトプロロールラセミ化合物の塩酸塩形態であり、そして 局所麻酔剤はロピバカインである請求項5記載の組み合せ。 15.メトプロロールはメトプロロールラセミ化合物の酒石酸塩形態であり、そし て局所麻酔剤はロピバカインである請求項5記載の組み合せ。 16.β−受容体ブロッカーの濃度は0.20〜120μモル/ml、好ましくは0.20〜30 μモル/mlの範囲である請求項1〜15記載の組み合せ。 17.局所麻酔剤の濃度は0.20〜120μモル/ml、好ましくは0.20〜30μモル/ml の範囲である請求項1〜16記載の組み合せ。 18.痛みを治療するための請求項1記載の組み合せ。 19.痛みの治療剤の製造における請求項1記載の組み合せの使用。 20.β−受容体ブロッカーおよび/または局所麻酔剤は静脈内、脊髄または硬膜 外に投与される請求項19記載の使用。 21.活性成分としてのβ−受容体ブロッカー、そのエナンチオマーまたはその薬 学的に許容しうる塩および局所麻酔剤またはその薬学的に許容しうる塩を薬学的 に許容しうる基剤と一緒に含有する、治療に使用するための製剤。 22.治療的に活性な量のβ−受容体ブロッカー、そのエナンチオマーまたはその 薬学的に許容しうる塩および治療的に活性な量の薬所麻酔剤またはその薬学的に 許容しうる塩が同時にまたは連続的に投与される痛みの治療法。 23.β−受容体ブロッカー、そのエナンチオマーまたはその薬学的に許容しうる 塩および局所麻酔剤またはその薬学的に許容しうる 塩を薬学的に許容しうる基剤と混合することからなる請求項22記載の製剤の製造 法。 24.β−受容体ブロッカー、そのエナンチオマーまたはその薬学的に許容しうる 塩および局所麻酔剤またはその薬学的に許容しうる塩を場合により追加の薬剤と 一緒に含有するキット。 25.痛みの治療に使用される薬剤の製造におけるβ−受容体ブロッカーの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9401174A SE9401174D0 (sv) | 1994-04-07 | 1994-04-07 | New combination |
SE9401174-9 | 1994-04-07 | ||
PCT/SE1995/000314 WO1995027511A1 (en) | 1994-04-07 | 1995-03-24 | NEW COMBINATION OF A β-RECEPTOR BLOCKER AND A LOCAL ANAESTHETIC |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09511519A true JPH09511519A (ja) | 1997-11-18 |
JP3895767B2 JP3895767B2 (ja) | 2007-03-22 |
Family
ID=20393568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52627295A Expired - Fee Related JP3895767B2 (ja) | 1994-04-07 | 1995-03-24 | β−受容体ブロッカーおよび局所麻酔剤の新規な組合せ |
Country Status (12)
Country | Link |
---|---|
US (1) | US5856342A (ja) |
EP (1) | EP0754060B1 (ja) |
JP (1) | JP3895767B2 (ja) |
AT (1) | ATE233572T1 (ja) |
AU (1) | AU689577B2 (ja) |
DE (1) | DE69529819T2 (ja) |
DK (1) | DK0754060T3 (ja) |
ES (1) | ES2189828T3 (ja) |
IL (1) | IL113077A0 (ja) |
SE (1) | SE9401174D0 (ja) |
WO (1) | WO1995027511A1 (ja) |
ZA (1) | ZA952724B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001354554A (ja) * | 2000-06-16 | 2001-12-25 | Nagase Iyakuhin Kk | 鎮痛剤 |
ES2224899A1 (es) * | 2004-10-20 | 2005-03-01 | Ingenieria De Encofrados Y Servicios, S.L. | Cierre lateral para andamio de fachada. |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
SE9800139D0 (sv) | 1998-01-21 | 1998-01-21 | Astra Ab | New use |
ATE533509T1 (de) * | 2003-08-08 | 2011-12-15 | Ono Pharmaceutical Co | Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff |
US8412336B2 (en) | 2008-12-29 | 2013-04-02 | Autonomic Technologies, Inc. | Integrated delivery and visualization tool for a neuromodulation system |
US8494641B2 (en) | 2009-04-22 | 2013-07-23 | Autonomic Technologies, Inc. | Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism |
US9320908B2 (en) | 2009-01-15 | 2016-04-26 | Autonomic Technologies, Inc. | Approval per use implanted neurostimulator |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1806400A1 (de) * | 1968-10-31 | 1970-05-21 | Espe Pharm Praep | Pharmazeutisches Produkt,insbesondere injizierbares Lakalanaesthetikum |
CA2142103C (en) * | 1992-08-28 | 2003-07-08 | Haim Aviv | Submicron emulsions as ocular drug delivery vehicles |
-
1994
- 1994-04-07 SE SE9401174A patent/SE9401174D0/xx unknown
-
1995
- 1995-03-22 IL IL11307795A patent/IL113077A0/xx unknown
- 1995-03-24 AT AT95916068T patent/ATE233572T1/de not_active IP Right Cessation
- 1995-03-24 WO PCT/SE1995/000314 patent/WO1995027511A1/en active IP Right Grant
- 1995-03-24 ES ES95916068T patent/ES2189828T3/es not_active Expired - Lifetime
- 1995-03-24 JP JP52627295A patent/JP3895767B2/ja not_active Expired - Fee Related
- 1995-03-24 DK DK95916068T patent/DK0754060T3/da active
- 1995-03-24 AU AU22697/95A patent/AU689577B2/en not_active Ceased
- 1995-03-24 DE DE69529819T patent/DE69529819T2/de not_active Expired - Fee Related
- 1995-03-24 EP EP95916068A patent/EP0754060B1/en not_active Expired - Lifetime
- 1995-04-03 ZA ZA952724A patent/ZA952724B/xx unknown
- 1995-04-24 US US08/428,170 patent/US5856342A/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001354554A (ja) * | 2000-06-16 | 2001-12-25 | Nagase Iyakuhin Kk | 鎮痛剤 |
JP4494594B2 (ja) * | 2000-06-16 | 2010-06-30 | ナガセ医薬品株式会社 | 鎮痛剤 |
ES2224899A1 (es) * | 2004-10-20 | 2005-03-01 | Ingenieria De Encofrados Y Servicios, S.L. | Cierre lateral para andamio de fachada. |
Also Published As
Publication number | Publication date |
---|---|
ATE233572T1 (de) | 2003-03-15 |
ZA952724B (en) | 1995-10-09 |
EP0754060B1 (en) | 2003-03-05 |
SE9401174D0 (sv) | 1994-04-07 |
DE69529819T2 (de) | 2004-02-12 |
AU689577B2 (en) | 1998-04-02 |
ES2189828T3 (es) | 2003-07-16 |
US5856342A (en) | 1999-01-05 |
AU2269795A (en) | 1995-10-30 |
DK0754060T3 (da) | 2003-04-22 |
IL113077A0 (en) | 1995-06-29 |
JP3895767B2 (ja) | 2007-03-22 |
DE69529819D1 (de) | 2003-04-10 |
WO1995027511A1 (en) | 1995-10-19 |
EP0754060A1 (en) | 1997-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Giovannitti et al. | Pharmacology of local anesthetics used in oral surgery | |
Wiles et al. | Local anaesthetics and adjuvants–future developments | |
JPH10505864A (ja) | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 | |
JP2002541097A (ja) | 線維筋痛症及び関連症状の治療におけるフルピルチン | |
Eisenach | Alpha-2 agonists and analgesia | |
JPH09511519A (ja) | β−受容体ブロッカーおよび局所麻酔剤の新規な組合せ | |
Khanna et al. | Comparative evaluation of bupivacaine plain versus bupivacaine with fentanyl in spinal anaesthesia in geriatric patients | |
JP2620642B2 (ja) | 麻薬性鎮痛剤とベンゾジアゼピンとを組み合わせて非経口投与した後に観察される平均血圧の低下を拮抗させるための医薬品 | |
JPH11511465A (ja) | ハロアルキルアミン及び局所麻酔薬製剤並びに反射性交感神経性ジストロフィー(rsd)の治療法 | |
EP0862462B1 (en) | Combination of a beta-receptor blocker and an opioid | |
CA2186601C (en) | New combination of a .beta.-receptor blocker and a local anaesthetic | |
Goudas | Clonidine | |
Vogt et al. | A preoperative retrobulbar block in patients undergoing scleral buckling reduces pain, endogenous stress response, and improves vigilance | |
d'Amours et al. | Perioperative drugs and postoperative pain management | |
Yun et al. | 8 New amide local anaesthetics for obstetric use | |
Varner et al. | Chloroephedrine: contaminant of methamphetamine synthesis with cardiovascular activity | |
Yadhuraj | A comparative study between 0.75% ropivacaine plain and 0.75% ropivacaine with opioid additive buprenorphine for supraclavicular brachial plexus block in upper limb surgeries | |
Öztekın et al. | Comparison of the antiemetic efficacy of tropisetron and droperidol with patient-given tramadol | |
Manjunath | A Randomised Clinical Trial To Compare The Effectiveness Between Bupivacaine And Bupivacaine-Clonidine Combination In Brachial Plexus Block By Supraclavicular Approach | |
Mathews | Efficiency of Buprinorphine in 2% Lignocain 1: 80,000 Combination for Post-Operative Anlgesia Afterof Impacted Mandibular Third Molar-A Prospective Clinical Study | |
AU700902B2 (en) | Analgesic agent and its use | |
JP6419074B2 (ja) | ショックの治療に使用するためのアドレナリンと抗うつ剤との組み合わせ | |
Devireddy | A Study to Evaluate the Effects of Unilateral Spinal Anaesthesia with Intrathecal Hyperbaric Bupivacaine and Adjuvant Fentanyl Using 27 G Spinal Needle in Elective Lower Limb Surgeries | |
Morrison et al. | Pain management | |
Sannakki | Comparitive Study To Know The Efficacy Of Dexmedetomidine & Clonidine As An Adjuvant To Local Anesthesia In Supraclavicular Brachial Plexus Block |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060313 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060821 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20061005 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061215 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |